Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02421900

Enrollment

100

Registered

2015-04-21

Start date

2015-04-01

Completion date

2020-03-31

Last updated

2018-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

The purpose of this study is 1) to characterize T-cell response in patients with atrial fibrillation, and 2) to analyze the changes of T-cell response after radio-frequency catheter ablation of atrial fibrillation. First, immune-phenotyping and cytokine profiling of T cells from patients with atrial fibrillation will performed. Next the difference of T-cell immunity among various type of atrial fibrillation patients will be analyzed. Finally the changes of T-cell response and cytokines after radio-frequency catheter ablation of atrial fibrillation will be assessed.

Interventions

OTHERradio-frequency catheter ablation of atrial fibrillation

radio-frequency catheter ablation of atrial fibrillation

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who consent with study * patients with age more than19 * patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation

Exclusion criteria

* Patients who do not agree with study inclusion * Permanent AF refractory to electrical cardioversion * AF with rheumatic valvular disease * Patients with left atrial diameter greater than 60mm * Patients with age less than 19 * Patient with malignant tumor and chronic infection disease * Patient are given immune inhibitor and steroidal anti-inflammatory drug within 2weeks

Design outcomes

Primary

Measure	Time frame	Description
The frequency (%) of specific marker-expressing cells among CD4 or CD8 T-subsets	1 year	* Immunosenescence marker: CD28, CD57 * Activation marker: CD38, HLA-DR * Differentiation marker: CCR7, CD45RA

Secondary

Measure	Time frame	Description
The frequency (%) of cytokine-secreting cells among CD4 or CD8 T-subsets	1 year	* Proinflammatory cytokine: IFN-gamma, TNF-alpha * Cytotoxic molecule: granzyme B, perforin

Countries

South Korea

Contacts

Primary ContactHui-Nam Pak, MD, PhD

hnpak@yuhs.ac82-2-2228-8459

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026